ImmBio Additional Series C Funding Secured To Progress Its Product Portfolio
ImmunoBiology Ltd is pleased to report that it has closed the second part of its C series Round, following successful achievement of a number of milestones.... Read more
Latest News
ImmunoBiology (ImmBio) Extend Its Collaboration With Eden Biodesign To Develop A New Generation Vaccine For Influenza
Eden Biodesign Ltd. have elected to extend their initial collaboration to develop ImmBio’s innovative influenza vaccine... Read more
Eden Biodesign And ImmunoBiology (ImmBio) Develop Next Generation Vaccine For The Prevention Of Influenza
Eden Biodesign Ltd, an innovative provider of development and manufacturing services for new medicines, announced today that it has been selected by ImmBio... Read more
ImmBio Therapeutics Secures EEDA Funding
ImmBio Therapeutics Ltd is pleased to announce that it has been awarded a Proof of Concept grant by the East of England Development Agency (“EEDEA”)... Read more
ImmBio Appoints Chairman and Non-Executive Directors
ImmunoBiology Ltd (“ImmBio”) has appointed two new non-executives directors to the Board, reconstituted after completion of its Series C funding round... Read more
ImmBio and Scancell Announce Collaboration and Licensing of ImmunoBodies
ImmunoBiology (“ImmBio”), the Cambridge-based anti-infectives vaccine developer has entered into an agreement to apply Scancell’s ImmunoBody™ technology to selected ant-infective targets... Read more